Ekso Bionics (NASDAQ:EKSO) Announces Earnings Results

Ekso Bionics (NASDAQ:EKSO) posted its earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07), Zacks reports. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%.

Ekso Bionics Price Performance

EKSO traded down $0.04 during trading on Monday, reaching $0.48. 225,704 shares of the company were exchanged, compared to its average volume of 348,824. The company’s 50-day moving average is $0.61 and its two-hundred day moving average is $0.83. The company has a market cap of $10.61 million, a price-to-earnings ratio of -0.74 and a beta of 1.46. Ekso Bionics has a 12-month low of $0.47 and a 12-month high of $2.16. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28.

Analyst Ratings Changes

Several research firms have recently issued reports on EKSO. StockNews.com assumed coverage on Ekso Bionics in a report on Monday. They issued a “hold” rating for the company. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Ekso Bionics in a research note on Tuesday, January 14th.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.